Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
Details : PRAX-944 (ulixacaltamide) is a highly selective small molecule inhibitor of T-type calcium channels designed for the treatment of essential tremors.
Product Name : PRAX-944
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2025
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Piper Sandler
Deal Size : $150.0 million
Deal Type : Public Offering
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
Details : The proceeds will complete the development of PRAX-944 (ulixacaltamide) in Phase 3 studies for essential tremor and clinical development of PRAX-628, PRAX-562, and PRAX-222 for various epilepsies.
Product Name : PRAX-944
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 01, 2024
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Piper Sandler
Deal Size : $150.0 million
Deal Type : Public Offering
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Piper Sandler
Deal Size : Undisclosed
Deal Type : Public Offering
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
Details : The proceeds will complete the development of PRAX-944 (ulixacaltamide) in Phase 3 studies for essential tremor and clinical development of PRAX-628, PRAX-562, and PRAX-222 for various epilepsies.
Product Name : PRAX-944
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 01, 2024
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Piper Sandler
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Tenacia Biotechnology
Deal Size : $279.0 million
Deal Type : Licensing Agreement
Praxis Partners with Tenacia for Ulixacaltamide in Greater China
Details : Tenacia will develop and commercialize PRAX-944 (ulixacaltamide), a T-type calcium channel inhibitor for essential tremor, in Greater China.
Product Name : PRAX-944
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
May 01, 2024
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Tenacia Biotechnology
Deal Size : $279.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRAX-944 (ulixacaltamide) is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical circuit correlated with tremor activity.
Product Name : PRAX-944
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2023
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRAX-944 (ulixacaltamide) is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical circuit correlated with tremor activity.
Product Name : PRAX-944
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Piper Sandler
Deal Size : $63.3 million
Deal Type : Public Offering
Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
Details : The net proceeds will advance the development of PRAX-944 (ulixacaltamide), a novel selective T-type calcium channel blocker, in two Phase 3 studies for essential tremor and to continue clinical development of PRAX-562, PRAX-222 and PRAX-628 for various ...
Product Name : PRAX-944
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 22, 2023
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Piper Sandler
Deal Size : $63.3 million
Deal Type : Public Offering
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Piper Sandler
Deal Size : $59.1 million
Deal Type : Public Offering
Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering
Details : The net proceeds will advance the development of PRAX-944 (ulixacaltamide), a novel selective T-type calcium channel blocker, in two Phase 3 studies for essential tremor and to continue clinical development of PRAX-562, PRAX-222 and PRAX-628 for various ...
Product Name : PRAX-944
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 15, 2023
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Piper Sandler
Deal Size : $59.1 million
Deal Type : Public Offering
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRAX-944 (ulixacaltamide) is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical circuit correlated with tremor activity.
Product Name : PRAX-944
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2023
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the open-label period through Day 42, patients treated with PRAX-944 demonstrated mean improvement from baseline of 42% in the Modified Activities of Daily Living (ADL) score (N=11, nominal p<0.05).
Product Name : PRAX-944
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 05, 2022
Lead Product(s) : Ulixacaltamide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable